Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31088807 | 0.98 | GAA (0.40) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL27300102 | 0.91 | GAA (0.43) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL9796453 | 0.84 | KDM4E (0.40) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL31089194 | 0.83 | TSHR (0.41) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL28567972 | 0.81 | CYP3A4 (0.35) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6545234 | 0.81 | CYP3A4 (0.35) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6544313 | 0.81 | KDM4E (0.39) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL27497690 | 0.81 | KDM4E (0.45) | KDM4EGAAMGAMSIMGAM2 | |
| SCHEMBL6545165 | 0.79 | ALDH1A1 (0.38) | GAAALDH1A1MAPTTSHR | |
| SCHEMBL14085473 | 0.77 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | claimed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | claimed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | claimed |
| WO-2024175907-A1 | MACROCYCLIC ALPHA4BETA7 INTEGRIN INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023125935-A1 | BENZOPYRIDINE DERIVATIVE REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20200400696-A1 | Compounds and Methods for Use in Detecting Gabapentin | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2020-12-24 | — | — | US | disclosed |
| WO-2019152688-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152688-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20090062392-A1 | DEUTERIUM-ENRICHED GABAPENTIN | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062392-A1 | DEUTERIUM-ENRICHED GABAPENTIN | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062392-A1 | DEUTERIUM-ENRICHED GABAPENTIN | GABRD, SLC6A13, SLC6A1 | KDM4E 1905/4885GAA 2649/4885MGAM 2801/4885 |
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SLC7A1, MRPL21, BCAT1 | KDM4E 3993/4885GAA 2650/4885MGAM 782/4885 |
| US-20200400696-A1 | Compounds and Methods for Use in Detecting Gabapentin | GABRE, GABRG3, GABRB2 | KDM4E 4009/4885GAA 856/4885MGAM 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.